Respiratory Syncytial Virus Infections
📧 Sign up to get email alerts when something new happens for Respiratory Syncytial Virus Infections.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-08-27EMA Authorised: mResvia (Single-stranded 5' capped mRNA encoding the respiratory syncytial virus glycoprotein F stabilised in the prefusion conformation) — Moderna Biotech Spain, S.L.
mResvia, an mRNA vaccine encoding RSV F protein in prefusion conformation, has been authorised in the EU for respiratory syncytial virus inf…
-
EMA approval · 2026-08-06EMA Authorised: Abrysvo (respiratory syncytial virus vaccine (bivalent, recombinant)) — Pfizer Europe MA EEIG
EMA has authorised Abrysvo, a bivalent recombinant RSV vaccine, for respiratory syncytial virus infections with accelerated assessment.
-
CLINICAL_TRIALS trial_result · 2026-07-29Clinical Trial Update: An Extension and Crossover Vaccination Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 60 Years of Age and Above Who Participated in RSV OA=ADJ-006 Study [Phase 3]
A Phase 3 extension and crossover vaccination study evaluating immune response and safety of an RSV vaccine in adults aged 60+ who participa…
-
CLINICAL_TRIALS trial_result · 2026-06-23Clinical Trial Results: A Study in India on the Immune Response and Safety of a Respiratory Syncytial Virus (RSV) Older Adults (OA) Vaccine When Given to Older Adults 60 Years of Age and Above and Adults 50-59 Years of Age at Increased Risk (AIR) of Respiratory Syncytial Virus Lower Respiratory Tract Disease (RSV-LRTD) [Phase 3]
Phase 3 trial results evaluating safety and immune response of an RSV vaccine in older adults (60+) and high-risk adults (50-59) with RSV-LR…
-
CLINICAL_TRIALS trial_result · 2026-04-20Clinical Trial Update: An Extension and Crossover Vaccination Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 60 Years of Age and Above Who Participated in RSV OA=ADJ-006 Study [Phase 3]
This document reports an extension and crossover study of an RSV vaccine in adults 60 years and older who participated in a prior RSV trial;…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA approval · 2026-03-23EMA Authorised: Arexvy — GlaxoSmithKline Biologicals S.A.
The EMA has authorised Arexvy by GlaxoSmithKline Biologicals S.A. for respiratory syncytial virus infections. Decision date: 19 February 202…
-
CLINICAL_TRIALS research · 2026-03-06Clinical Trial Update: A Study Evaluating Persistence of the Immune Response of the Adjuvanted Respiratory Syncytial Virus (RSV) Vaccine and the Safety and Immune Response Following Revaccination in Adults 18 Years of Age and Above Who Received Lung or Kidney Transplant [Phase 2]
A Phase 2 clinical trial evaluating the persistence of immune response and safety after revaccination with an adjuvanted RSV vaccine in adul…
-
CLINICAL_TRIALS trial_result · 2026-02-11Clinical Trial Update: A Study on the Immune Response, Safety and the Occurrence of Respiratory Syncytial Virus (RSV)-Associated Respiratory Tract Illness After Administration of RSV OA Vaccine in Adults 60 Years and Older [Phase 3]
Phase 3 study evaluating immune response, safety, and RSV-associated respiratory illness after RSV OA Vaccine in adults aged 60 and older ha…
-
CLINICAL_TRIALS research · 2026-02-09Clinical Trial Update: Azithromycin Treatment for Respiratory Syncytial Virus-induced Respiratory Failure in Children [Phase 3]
A Phase 3 trial is evaluating azithromycin for respiratory failure caused by respiratory syncytial virus in children. The study is currently…
-
CLINICAL_TRIALS research · 2026-01-27Clinical Trial Update: Evaluating the Benefits of RSV Maternal Vaccination Using a Scottish National Dataset
Pfizer is evaluating the benefits of maternal RSV vaccination using Scotland's national health dataset, and the study is currently not recru…
-
CLINICAL_TRIALS trial_result · 2025-12-26Clinical Trial Update: A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a COVID-19 mRNA Vaccine in Adults Aged 50 Years and Above [Phase 3]
A Phase 3 trial evaluated the immune response and safety of an RSV vaccine in adults 50 years and older, given alone or together with a COVI…
-
EMA approval · 2025-11-26EMA Authorised: mResvia (Respiratory syncytial virus mRNA vaccine (nucleoside modified)) — Moderna Biotech Spain, S.L.
The EMA has authorised mResvia, a nucleoside-modified RSV mRNA vaccine by Moderna Biotech Spain, S.L., for prevention of respiratory syncyti…
-
CLINICAL_TRIALS trial_result · 2025-05-18Clinical Trial Update: Study to Assess the Immune Response, the Safety and the Reactogenicity of Respiratory Syncytial Virus (RSV) Prefusion Protein 3 Older Adult (OA) (RSVPreF3 OA) Investigational Vaccine When co Administered With PCV20 in Older Adults [Phase 3]
A Phase 3 study assessing the immune response, safety, and reactogenicity of the RSVPreF3 OA vaccine when co-administered with PCV20 in olde…
-
CLINICAL_TRIALS trial_result · 2025-02-04Clinical Trial Update: A Phase 2a Study to Evaluate Orally Administered ALS-008176 in Adults Hospitalized With a Respiratory Syncytial Virus [Phase 2]
Phase 2a trial evaluating orally administered ALS-008176 in adults hospitalized with respiratory syncytial virus has completed.
-
CLINICAL_TRIALS trial_result · 2025-02-03Clinical Trial Update: A Phase 2a Study to Evaluate ALS-008176 in the Virus Challenge Model [Phase 2]
This document reports the completion of a Phase 2a trial evaluating ALS-008176 in a virus challenge model for Respiratory Syncytial Virus in…
-
CLINICAL_TRIALS trial_result · 2025-02-03Clinical Trial Update: A Study of ALS-008176 in Infants Hospitalized With RSV [Phase 1]
A Phase 1 study evaluating ALS-008176 in infants hospitalized with Respiratory Syncytial Virus infections has completed.
-
CLINICAL_TRIALS trial_result · 2024-10-01Clinical Trial Update: A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral Deuremidevir Hydrobromide for Suspension [Phase 1]
A Phase 1 study evaluating the safety, tolerability, and pharmacokinetics of oral Deuremidevir Hydrobromide for Suspension has been complete…
-
CLINICAL_TRIALS trial_result · 2024-09-19Clinical Trial Update: Safety and Immunogenicity of the RSV D46cpΔM2-2 Vaccine in RSV-Seropositive Children and RSV-Seronegative Infants and Children [Phase 1]
Phase 1 trial results evaluating the safety and immunogenicity of the RSV D46cpΔM2-2 vaccine in RSV-seropositive children and RSV-seronegati…
-
CLINICAL_TRIALS research · 2024-09-19Clinical Trial Update: Prospective Surveillance of Respiratory Syncytial Virus Disease in Infants and Toddlers
A prospective surveillance study on Respiratory Syncytial Virus infections in infants and toddlers has completed, sponsored by Sanofi Pasteu…
-
CLINICAL_TRIALS trial_result · 2024-09-05Clinical Trial Update: A Phase III, Double-blind Study to Assess Safety and Efficacy of an RSV Maternal Unadjuvanted Vaccine, in Pregnant Women and Infants Born to Vaccinated Mothers [Phase 3]
This Phase 3 double-blind trial of an RSV maternal unadjuvanted vaccine in pregnant women and their infants was terminated, and results were…
-
CLINICAL_TRIALS trial_result · 2024-05-21Clinical Trial Update: A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 50-59 Years of Age, Including Adults at Increased Risk of Respiratory Syncytial Virus Lower Respiratory Tract Disease, Compared to Older Adults 60 Years of Age and Above [Phase 3]
Phase 3 study assessing safety and immune response of an RSV vaccine in adults aged 50-59 (including at higher risk for RSV lower respirator…
-
CLINICAL_TRIALS trial_result · 2024-05-16Clinical Trial Update: A Study to Learn About Effect of Sisunatovir in Healthy Adult Male Participants [Phase 1]
Pfizer completed a Phase 1 study to evaluate the safety, tolerability, and pharmacokinetics of Sisunatovir in healthy adult male participant…
-
CLINICAL_TRIALS trial_result · 2024-04-12Clinical Trial Update: Human Interferon α1b Inhalation Solution Against Respiratory Syncytial Virus in Children With Lower Respiratory Tract Infections [Phase 3]
Phase 3 trial investigating inhaled human interferon α1b solution for respiratory syncytial virus infections in children is currently recrui…
-
CLINICAL_TRIALS trial_result · 2024-03-15Clinical Trial Update: A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone or Co-administered With an Adjuvanted Vaccine Against Influenza in Adults Aged 65 Years and Above [Phase 3]
Phase 3 study evaluating the immune response and safety of a respiratory syncytial virus vaccine given alone or co-administered with an adju…
-
CLINICAL_TRIALS trial_result · 2024-02-29Clinical Trial Update: A Dose Finding Study of VN-0200 [Phase 2]
Phase 2 dose-finding trial of VN-0200 for respiratory syncytial virus infections has been completed.